Smith Group Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Smith Group Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-24,510	Closed	-$3.83M	–	348
2020 Q4	$3.83M	Sell	24,510 -11,900	-33%	-$1.53M	0.22%	72
2020 Q3	$4.17M	Sell	36,410 -60	-0.2%	-$6.47K	0.22%	83
2020 Q2	$4.09M	Sell	36,470 -16,920	-32%	-$1.8M	0.23%	83
2020 Q1	$4.79M	Sell	53,390 -2,270	-4%	-$223K	0.26%	82
2019 Q4	$6.02M	Buy	+55,660	New	+$5.95M	0.25%	84
2015 Q1	–	Sell	-87,877	Closed	-$16.3M	–	463
2014 Q4	$16.3M	Buy	87,877 +10	+0%	+$1.85K	0.57%	67
2014 Q3	$14.6M	Buy	87,867 +567	+0.6%	+$93.1K	0.54%	71
2014 Q2	$13.6M	Buy	+87,300	New	+$13.8M	0.5%	73

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smith Group Asset Management's ALXN Position: Q1 2021 in Review

Smith Group Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 24,510 shares — an estimated $3.83M sold.

Smith Group Asset Management first reported a position in ALXN in Q2 2014 and held it in 8 quarters. The position peaked at $16.3M in Q4 2014. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Smith Group Asset Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Smith Group Asset Management sold 24,510 Alexion Pharmaceuticals shares in Q1 2021, an estimated $3.83M.
Smith Group Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 8 quarters.
Smith Group Asset Management's Alexion Pharmaceuticals position peaked at $16.3M in Q4 2014.
754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Smith Group Asset Management's 13F filing for Q1 2021, filed 7 May 2021.